|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ADAMTS9-CFTR (FusionGDB2 ID:2228) |
Fusion Gene Summary for ADAMTS9-CFTR |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ADAMTS9-CFTR | Fusion gene ID: 2228 | Hgene | Tgene | Gene symbol | ADAMTS9 | CFTR | Gene ID | 56999 | 1080 |
| Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 9 | CF transmembrane conductance regulator | |
| Synonyms | - | ABC35|ABCC7|CF|CFTR/MRP|MRP7|TNR-CFTR|dJ760C5.1 | |
| Cytomap | 3p14.1 | 7q31.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | A disintegrin and metalloproteinase with thrombospondin motifs 9a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9 | cystic fibrosis transmembrane conductance regulatorcAMP-dependent chloride channelchannel conductance-controlling ATPasecystic fibrosis transmembrane conductance regulatingcystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-f | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | Q9P2N4 | P13569 | |
| Ensembl transtripts involved in fusion gene | ENST00000295903, ENST00000498707, ENST00000467257, ENST00000459780, | ENST00000003084, ENST00000454343, ENST00000608965, | |
| Fusion gene scores | * DoF score | 7 X 7 X 5=245 | 13 X 15 X 10=1950 |
| # samples | 7 | 13 | |
| ** MAII score | log2(7/245*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(13/1950*10)=-3.90689059560852 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ADAMTS9 [Title/Abstract] AND CFTR [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ADAMTS9(64852932)-CFTR(117170953), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ADAMTS9 | GO:0006508 | proteolysis | 12514189 |
| Tgene | CFTR | GO:0015701 | bicarbonate transport | 15010471|19019741 |
| Tgene | CFTR | GO:0034976 | response to endoplasmic reticulum stress | 21884936|28067262 |
| Tgene | CFTR | GO:1902476 | chloride transmembrane transport | 11524016|11707463|19019741 |
| Tgene | CFTR | GO:1902943 | positive regulation of voltage-gated chloride channel activity | 22006324 |
| Tgene | CFTR | GO:1904322 | cellular response to forskolin | 15010471|19621064 |
| Fusion gene breakpoints across ADAMTS9 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across CFTR (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | KIRC | TCGA-CJ-4905-01A | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
Top |
Fusion Gene ORF analysis for ADAMTS9-CFTR |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000295903 | ENST00000003084 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000295903 | ENST00000454343 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-intron | ENST00000295903 | ENST00000608965 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000498707 | ENST00000003084 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000498707 | ENST00000454343 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-intron | ENST00000498707 | ENST00000608965 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000467257 | ENST00000003084 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000467257 | ENST00000454343 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-intron | ENST00000467257 | ENST00000608965 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000459780 | ENST00000003084 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-3CDS | ENST00000459780 | ENST00000454343 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| intron-intron | ENST00000459780 | ENST00000608965 | ADAMTS9 | chr3 | 64852932 | + | CFTR | chr7 | 117170953 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ADAMTS9-CFTR |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ADAMTS9-CFTR |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ADAMTS9 | CFTR |
| FUNCTION: Cleaves the large aggregating proteoglycans, aggrecan (at the '1838-Glu-|-Ala-1839' site) and versican (at the '1428-Glu-|-Ala-1429' site). Has a protease-independent function in promoting the transport from the endoplasmic reticulum to the Golgi apparatus of a variety of secretory cargos. {ECO:0000269|PubMed:12514189, ECO:0000269|PubMed:22419820}. | FUNCTION: Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis (PubMed:26823428). Mediates the transport of chloride ions across the cell membrane (PubMed:10792060, PubMed:11524016, PubMed:11707463, PubMed:12519745, PubMed:15010471, PubMed:12588899, PubMed:17036051, PubMed:19398555, PubMed:19621064, PubMed:22178883, PubMed:25330774, PubMed:1712898, PubMed:8910473, PubMed:9804160, PubMed:12529365, PubMed:17182731, PubMed:26846474, PubMed:28087700). Channel activity is coupled to ATP hydrolysis (PubMed:8910473). The ion channel is also permeable to HCO(3-); selectivity depends on the extracellular chloride concentration (PubMed:15010471, PubMed:19019741). Exerts its function also by modulating the activity of other ion channels and transporters (PubMed:12403779, PubMed:22178883, PubMed:22121115, PubMed:27941075). Plays an important role in airway fluid homeostasis (PubMed:16645176, PubMed:19621064, PubMed:26823428). Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens (PubMed:14668433, PubMed:16645176, PubMed:26823428). Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex (PubMed:17434346, PubMed:27941075, PubMed:17182731). Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:17182731). Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:27941075). May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7 (PubMed:12403779). Can inhibit the chloride channel activity of ANO1 (PubMed:22178883). Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation (PubMed:19923167, PubMed:27714810). {ECO:0000269|PubMed:10792060, ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:12403779, ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12529365, ECO:0000269|PubMed:12588899, ECO:0000269|PubMed:14668433, ECO:0000269|PubMed:15010471, ECO:0000269|PubMed:16645176, ECO:0000269|PubMed:17036051, ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:17182731, ECO:0000269|PubMed:19019741, ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:19621064, ECO:0000269|PubMed:22178883, ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:26823428, ECO:0000269|PubMed:26846474, ECO:0000269|PubMed:27714810, ECO:0000269|PubMed:27941075, ECO:0000269|PubMed:28087700, ECO:0000269|PubMed:8910473, ECO:0000269|PubMed:9804160, ECO:0000305|PubMed:19923167}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ADAMTS9-CFTR |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ADAMTS9-CFTR |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ADAMTS9-CFTR |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | CFTR | P13569 | DB00887 | Bumetanide | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB00887 | Bumetanide | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB01016 | Glyburide | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB01016 | Glyburide | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB01050 | Ibuprofen | Inhibitor | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB01050 | Ibuprofen | Inhibitor | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB04941 | Crofelemer | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB04941 | Crofelemer | Antagonist | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB08820 | Ivacaftor | Potentiator | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB08820 | Ivacaftor | Potentiator | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB09280 | Lumacaftor | Modulator | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB09280 | Lumacaftor | Modulator | Small molecule | Approved |
| Tgene | CFTR | P13569 | DB09213 | Dexibuprofen | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | CFTR | P13569 | DB09213 | Dexibuprofen | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | CFTR | P13569 | DB11712 | Tezacaftor | Activator | Small molecule | Approved|Investigational |
| Tgene | CFTR | P13569 | DB11712 | Tezacaftor | Activator | Small molecule | Approved|Investigational |
| Tgene | CFTR | P13569 | DB15444 | Elexacaftor | Modulator | Small molecule | Approved|Investigational |
| Tgene | CFTR | P13569 | DB15444 | Elexacaftor | Modulator | Small molecule | Approved|Investigational |
Top |
Related Diseases for ADAMTS9-CFTR |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ADAMTS9 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 2 | CTD_human |
| Hgene | ADAMTS9 | C1855681 | Nephronophthisis, familial juvenile | 1 | ORPHANET |
| Tgene | CFTR | C0010674 | Cystic Fibrosis | 91 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | CFTR | C0392164 | Pulmonary Cystic Fibrosis | 15 | CTD_human |
| Tgene | CFTR | C1527396 | Fibrocystic Disease of Pancreas | 15 | CTD_human |
| Tgene | CFTR | C0403814 | Congenital bilateral aplasia of vas deferens | 8 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | CFTR | C0238339 | Hereditary pancreatitis | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Tgene | CFTR | C0021364 | Male infertility | 2 | CTD_human |
| Tgene | CFTR | C0030305 | Pancreatitis | 2 | CTD_human |
| Tgene | CFTR | C0267937 | Acute recurrent pancreatitis | 2 | ORPHANET |
| Tgene | CFTR | C0339985 | Idiopathic bronchiectasis | 2 | ORPHANET |
| Tgene | CFTR | C0848676 | Subfertility, Male | 2 | CTD_human |
| Tgene | CFTR | C0917731 | Male sterility | 2 | CTD_human |
| Tgene | CFTR | C0001973 | Alcoholic Intoxication, Chronic | 1 | PSYGENET |
| Tgene | CFTR | C0004509 | Azoospermia | 1 | CTD_human |
| Tgene | CFTR | C0008340 | Choledochal Cyst | 1 | CTD_human |
| Tgene | CFTR | C0008370 | Cholestasis | 1 | GENOMICS_ENGLAND |
| Tgene | CFTR | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
| Tgene | CFTR | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| Tgene | CFTR | C0009439 | Choledochal Cyst, Type I | 1 | CTD_human |
| Tgene | CFTR | C0013146 | Drug abuse | 1 | CTD_human |
| Tgene | CFTR | C0013170 | Drug habituation | 1 | CTD_human |
| Tgene | CFTR | C0013222 | Drug Use Disorders | 1 | CTD_human |
| Tgene | CFTR | C0019284 | Diaphragmatic Hernia | 1 | CTD_human |
| Tgene | CFTR | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
| Tgene | CFTR | C0035455 | Rhinitis | 1 | CTD_human |
| Tgene | CFTR | C0037199 | Sinusitis | 1 | CTD_human |
| Tgene | CFTR | C0038580 | Substance Dependence | 1 | CTD_human |
| Tgene | CFTR | C0038586 | Substance Use Disorders | 1 | CTD_human |
| Tgene | CFTR | C0085548 | Autosomal Recessive Polycystic Kidney Disease | 1 | CTD_human |
| Tgene | CFTR | C0149521 | Pancreatitis, Chronic | 1 | CTD_human |
| Tgene | CFTR | C0236969 | Substance-Related Disorders | 1 | CTD_human |
| Tgene | CFTR | C0740858 | Substance abuse problem | 1 | CTD_human |
| Tgene | CFTR | C1257796 | Choledochal Cyst, Type II | 1 | CTD_human |
| Tgene | CFTR | C1257797 | Choledochal Cyst, Type III | 1 | CTD_human |
| Tgene | CFTR | C1257798 | Choledochal Cyst, Type IV | 1 | CTD_human |
| Tgene | CFTR | C1257799 | Choledochal Cyst, Type V | 1 | CTD_human |
| Tgene | CFTR | C1510472 | Drug Dependence | 1 | CTD_human |
| Tgene | CFTR | C4316881 | Prescription Drug Abuse | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies